TaiMed completes Phase 2b enrollment for TMB-365/380 HIV therapy without pre-treatment resistance screening, with interim analysis expected by end...

LUMA trial shows BIIB122 failed to slow Parkinson's despite achieving robust target engagement in 648 early-stage patients over 48–144...

Tedopi Plus Pembrolizumab achieves 47% risk reduction in recurrent ovarian cancer, extending median PFS to 4.1 months in chemotherapy-exhausted...

EMA's CHMP recommended 8 new medicines and 13 indication extensions in May 2026—including camizestrant for ESR1+ breast cancer and...

Zongertinib shows early symptom relief in LUNG-1 PRO trial, with physical functioning improvements appearing within one week of first-line...

Aktis Oncology reports lower salivary gland toxicity for AKY-2519 compared to approved PSMA-targeted radiopharmaceuticals in prostate cancer.

TaiMed completes Phase 2b enrollment for TMB-365/380, an HIV therapy candidate designed to eliminate pre-treatment susceptibility screening requirements.

Infex's RESP-X showed reduced exacerbation rates in non-cystic fibrosis bronchiectasis patients colonized with Pseudomonas aeruginosa in Phase IIa data.

Tedopi Plus Pembrolizumab met its primary endpoint in the TEDOVA trial, reducing progression or death risk by 47% in...

BIIB122 failed to slow Parkinson's progression in a Phase 3 trial despite achieving over 90% target engagement in 648...